XML 208 R58.htm IDEA: XBRL DOCUMENT
v3.25.2

Subsequent Events (Details) $ in Millions | 1 Months Ended | 6 Months Ended | 12 Months Ended
--- | --- | --- | ---
Mar. 31, 2025 USD ($) employee | Feb. 28, 2025 item | Jan. 31, 2025 USD ($) | Jun. 30, 2025 employee | Dec. 31, 2024 employee
Employee Severance |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |
Reduction in workforce, number of employees | employee |  |  |  |  | 62
Reduction in workforce (as a percent) |  |  |  |  | 58.00%
Employee Severance | 2025 Cash Preservation Plan |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |
Reduction in workforce, number of employees | employee |  |  |  | 37 |
Reduction in workforce (as a percent) |  |  |  | 84.00% |
Moderna | Collaboration and License Agreement |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |
Number of oncology research targets, nominated |  | 10 |  |  |
Number of research targets, replacement nominations |  | 4 |  |  |
Number of oncology research targets, ceased development |  | 2 |  |  |
Number of autoimmune research targets, ceased development |  | 2 |  |  |
Number of oncology research targets |  | 12 |  |  |
Subsequent Event | Employee Severance | 2025 Cash Preservation Plan |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |
Reduction in workforce, number of employees | employee | 37 |  |  |  |
Reduction in workforce (as a percent) | 84.00% |  |  |  |
Expected cost with the reduction in workforce | $ | $ 3.8 |  |  |  |
Subsequent Event | Moderna |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |
Proceeds from collection of collaboration receivable | $ |  |  | $ 2.9 |  |
Subsequent Event | Moderna | Collaboration and License Agreement |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |
Number of oncology research targets, nominated |  | 10 |  |  |
Number of research targets, replacement nominations |  | 4 |  |  |
Number of oncology research targets, ceased development |  | 2 |  |  |
Number of autoimmune research targets, ceased development |  | 2 |  |  |
Number of oncology research targets |  | 12 |  |  |

X
- Definition Number of Research Targets, Gross, Oncology + References No definition available. + Details
Name: | carm_NumberOfResearchTargetsGrossOncology
Namespace Prefix: | carm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of Research Targets Nominated, Oncology + References No definition available. + Details
Name: | carm_NumberOfResearchTargetsNominatedOncology
Namespace Prefix: | carm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of Research Targets Nominated, Replacements + References No definition available. + Details
Name: | carm_NumberOfResearchTargetsNominatedReplacements
Namespace Prefix: | carm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of Research Targets, Terminated, Autoimmune + References No definition available. + Details
Name: | carm_NumberOfResearchTargetsTerminatedAutoimmune
Namespace Prefix: | carm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of Research Targets, Terminated, Oncology + References No definition available. + Details
Name: | carm_NumberOfResearchTargetsTerminatedOncology
Namespace Prefix: | carm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of cash inflow from the collection of receivables classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details
Name: | us-gaap_ProceedsFromCollectionOfOtherReceivables
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount expected to be recognized in earnings for the specified restructuring cost. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details
Name: | us-gaap_RestructuringAndRelatedCostExpectedCost1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The number of positions eliminated during the period as a result of restructuring activities. + References No definition available. + Details
Name: | us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s). + References No definition available. + Details
Name: | us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details
Name: | us-gaap_SubsequentEventLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RestructuringPlanAxis=carm_CashPreservationPlan2025Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_ModernaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |